The EPS projection of FibroGen, Inc (NASDAQ:FGEN) for quarter ended 2016-09-30 is $-0.5. Last week, the EPS forecast was $-0.5 against target of $-0.5, a month earlier. Two months ago, this estimate was $-0.5 versus forecast of $-0.5 three months earlier, implying a deviation of 0%.
FibroGen, Inc (NASDAQ:FGEN) stated that 18 days ago, its stock price was positively revised 1 times while negative revisions were 1.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 1, 2, and 2, correspondingly.
EPS estimate downgrade for FibroGen, Inc (NASDAQ:FGEN) in the preceding 30, 120, 60 and 90 days were 0, 1, 1, and 1, correspondingly.
FibroGen, Inc (NASDAQ:FGEN) EPS target for the quarter closed 1 was $-0.5, based on 3 recommendations. As reported on 2016-05-09 the EPS was $-0.45. The change was $0.24, implying a percentage deviation of 34.78%. The projections showed a standard deviation of 0.13.
Quarterly Sales Estimates
FibroGen, Inc (NASDAQ:FGEN) yearly sales prediction for the fiscal 2016 stands at $19.287 and the median estimate is at $19.325. Almost 4 analysts issued sales target.
Highest sales target is $24.5 while the lowest target is $14 showing standard deviation of 4.582%.
As many as 4 analysts have sales targets revised upside while 4 reduced sales estimates, implying a deviation of 0%.
Last month, 4 revised sales number projection on upside while 4 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast. FibroGen, Inc (NASDAQ:FGEN) announced that the deviation in forecast was -43.005%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...